Techniques for use of charcoal hemoperfusion in infants: Experience in two patients  by Chavers, Blanche M. et al.
Kidney International, Vol. 18 (1980), pp. 386 -389
TECHNICAL NOTE
Techniques for use of charcoal hemoperfusion in infants:
Experience in two patients
BLANCHE M. CHAVERS, CARL M. KJELLSTRAND, CLIFFORD WIEGAND, JAMES EBBEN, and
S. MICHAEL MAUER
Departments of Pediatrics and Medicine, The University of Minnesota Medical School, Minneapolis, Minnesota
Hemodialysis (HD) is used widely in the manage-
ment of children with renal failure. The techniques
and possible complications of HD treatment of in-
fants and children have been well described [1].
Charcoal hemoperfusion (CH) has received exten-
sive use in adult patients for the adsorption of a va-
riety of exogenous and endogenous intoxicants [2,
3]. Initially, CH resulted in complications such as
thrombocytopenia, charcoal embolism, leukopenia,
fibrinogenopenia, and hypocalcemia. The incidence
of these complications has been reduced markedly
by the use of polymer-coated charcoal [4, 5]. There
has been, however, little pediatric experience in the
use of CH. This paper indicates that the procedure
can be safely adapted for use even in the newborn
period.
Methods
Patients': Patient 1. A full-term 4-kg male with
ornithine transcarbamylase deficiency developed
extreme hyperammonemia unresponsive to con-
servative management. CH was used on day 4 of
life. This patient died 6 months after CH due to sep-
sis.
Patient 2. A full-term 3.2-kg male with complex
urologic anomalies requiring surgical drainage pro-
cedures was erroneously treated with excessive
dosages of chioramphenicol (200 mg/kg/day). After
the seventh dose of chioramphenicol, cardiovascu-
I Separate case reports of both patients have been accepted
for publication (See Ref. 10, 11).
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lar collapse (grey baby syndrome) developed. Thus,
on day 13 of life, with a chloramphenicol level of 93
.tglml, the patient underwent CH. This patient is
alive and well.
Previously described techniques of monitoring vi-
tal functions and body weight were used [1]. A neo-
natal infrared warmer was used to ensure stable
body temperature. Duration of the CH was 4 hours
in patient I and 3 hours in patient 2.
Blood access. Blood access for extracorporal cir-
culation in patient 1 consisted of an 8-French umbil-
ical catheter placed into the right atrium via the
right external jugular vein, serving as the blood exit
line, and a 5-French umbilical catheter placed in the
umbilical artery serving as the blood return line.
Blood flow rate used was 25 mllmin. A CH column
(Hemacol charcoal perfusion column, Warner-Chil-
cott, Morris Plains, New Jersey) containing gran-
ules coated with an acrylic hydrogel and the Gam-
bro Mini-Minor dialyzer (Gambro, Lund, Sweden)
were used.
Blood access for extracorporal circulation in pa-
tient 2 consisted of an 8-French umbilical catheter
placed into the right atrium via the right internal jug-
ular vein serving as the blood exit line, and a 5-
French umbilical catheter placed in the umbilical
vein serving as the blood return line. Blood flow
rate used was 30 mllmin. A CH cartridge (Gambro
Adsorba 300 C, Gambro, Lund, Sweden) containing
granules coated with cellulose and the Gambro
Mini-Minor dialyzer were used.
Circuit design. Charcoal hemoperfusion and HD
were performed in sequence, the charcoal columns
being placed before the dialyzers (Fig. 1). We used
commercial dialysate solution containing 2.5 mEqi
liter of calcium with 4 mg/dI of added phosphorus.
Filters present at the inlet and outlet of the CH col-
umns (Fig. 1) reduce the potential for embolization
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Fig. 1. Circuit design for charcoal hemoperfusion in pediatric
patients.
of charcoal. Manometers were placed before and af-
ter the CH columns to measure pressure differ-
entials across these devices. An increasing pres-
sure differential would indicate clotting of the col-
umn. A third manometer was placed following the
dialyzer to detect clotting of the dialyzer. An air-
leak detector was placed distal to the venous-drip
chamber.
Equipment priming. The CH columns were
rinsed with 500 ml of a 5% dextrose solution fol-
lowed by 2000 ml of heparinized (2 U heparinlml)
0.9% sodium chloride. The total extracorporal vol-
umes were 320 and 365 ml, including pediatric lines
(35 ml), Adsorba 300 C cartridge (260 ml), Hemacol
column (305 ml), and dialyzer (25 ml). Whole-blood
priming was used. At the end of the treatment, the
extracorporal blood was not transfused back.
Anticoagulation. Heparin (2 U) was added per
milliliter of priming blood, and 80 U of heparin per
kilogram of body wt were given as an i.v. bolus at
the start of extracorporal flow. This was followed
by continuous heparin infusion using 100 U/kg of
Table 1. Laboratory test resuitsa
Pre-CH Post-CH % Decrease
Patient 1
WBC,permm3 3,800 3,100 18.4
Hct,% 37.6 37 1.6
Platelets, per mm3 94,000 85,000 9.5
Ca,mg/dl 8.0 7.6 5
Patient 2
WBC,per mm3 12,300 7,600 38.2
Hct, % 30 36.5 —
Platelets, per mm3 135,000 92,000
151,000
(8 hr post CH)
31.8
Ca,mg/dl 8.6 6.5 24.4(obtained 8 hr
post-CH)
Abbreviations used are: WBC, white blood cell count per
cubic millimeter; Hct, hematocrit; Ca, calcium; CH, charcoal he-
moperfusion.
body wt in 100 ml of 0.9% sodium chloride. An in-
fusion rate of 0.5 mi/mm provided 30 U of heparin
per kilogram of body wt per hour. Lee White clot-
ting times were kept at 40 to 50 mm. Patient 1 was
allowed to recover spontaneously from the heparin
effect. Patient 2 received 2.5 mg of protamine in
three divided doses to prevent bleeding from post-
operative sites.
Results
Vital signs and body temperature did not deterio-
rate in either patient during the CH. There was no
malfunction of the extracorporal circuits and no evi-
dence of charcoal embolism. Both patients toler-
ated the CH well.
Patient 2 was noted to be acidotic and received
i.v. sodium bicarbonate prior to CH. Acid-base
studies 30 mm into CH showed continued acidosis
(serum bicarbonate, 9 mEq/liter), which responded
to i.v. sodium bicarbonate and did not recur. In this
patient, CH was associated with reversal of the
shock state.
Depression of white blood cell and platelet counts
occurred in both patients (Table 1). Platelet counts
returned to pre-CH levels within 24 hours. Coagu-
lation studies were normal at 12 hours following CH
in patient 2. Patient 1 received further hepariniza-
tion.
Serum calcium concentrations decreased during
CH despite HD. Although symptomatic hypocal-
cemia did not develop, patient 2 received i.v. cal-
cium gluconate for correction of hypocalcemia
present following CH.
Over the course of the extracorporal treatment,
the plasma glucose concentration increased from 66
to 129 mg/dl in patient 1. Posttreatment measure-
ments were not obtained in patient 2, but clinical
signs of hypoglycemia were not observed.
Discussion
We have demonstrated that CH can be performed
efficiently and safely in infants. Using previously
established methodology appropriately tailored to
the needs of the infant [1], we had no technical
problems during CH. This methodology involves
the incorporation of equipment and procedures nec-
essary to ensure stability of the small patient with
special attention to: (a) close monitoring of vital
functions; (b) continuous weight monitoring for the
immediate detection of fluid shifts; (c) whole-blood
priming of the circuit because, with presently avail-
able CH equipment, the extracorporal circuit vol-
ume greatly exceeds 10% of these patients' blood
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volumes. With this technique we were able to pre-
vent cardiodynamic instability.
The CH column should be rinsed with heparin-
ized 0.9% sodium chloride to remove fine particles
of charcoal and to allow heparin to adsorb to the
charcoal particle surfaces, presumably reducing
their thrombogenicity [3, 4, 6]. Dextrose rinsing of
the CH column reduces glucose adsorption during
CII [3, 6].
We placed a hemodialyzer in series with the CII
column to minimize acid-base, electrolyte distur-
bances and hypoglycemia and to prevent hypother-
mia, which we feared might have been serious com-
plications of the use of large charcoal columns in
such tiny babies. Decreases in serum calcium con-
centrations occurred, however, in both patients,
probably secondary to calcium adsorption by the
CH columns [3]. It is also possible that depletion of
serum calcium by the citrate in the donor blood
used for priming of the extracorporal circuit oc-
curred.
Thrombocytopenia secondary to platelet reten-
tion on the charcoal column and dialyzer mem-
branes [4, 7] occurs in spite of adequate hepariniza-
tion. Platelet loss is reduced to approximately 30%
or less [2, 4, 8] with the use of coated CH columns.
A 31% to 46% reduction in platelet count has been
reported with HD [7]. A recent report on the use of
CH in three children with Reye's syndrome sug-
gested that the method is unsafe because of diffi-
culty in detecting clotting in the CH column and sig-
nificant depletion of coagulation factors [9]. Low
flow rates and large CH columns were suggested as
causal factors of perhaps greater significance than
the coagulopathy intrinsic to Reye's syndrome.
These children were treated with the B-D Hemo-
detoxifier, which consists of 94 g of uncoated char-
coal affixed to polyester film and placed in a poly-
carbonate housing. The B-D Hemodetoxifier has
less blood compatibility than either the Adsorba 300
C or the Hemacol column [8]. Therefore, the poten-
tial for thrombocytopenia is greater when the B-D
Hemodetoxifier is used. Further, clotting in the ex-
tracorporal circuits, which occurred in the experi-
ence of Engle et a! [9] and which could contribute to
consumption of coagulation factors, was avoided in
our patients. Thus, major depletion of coagulation
factors needs not occur with use of the Adsorba 300
C or Hemacol CH columns if adequate heparization
is used.
We have reported previously that ammonia clear-
ances across the CH device in patient 1 was negli-
gible compared with simultaneous aqueous hemo-
dialysis where ammonia clearances approached
blood flow rates [10]. We therefore concluded that
CH was not indicated in the treatment of marked
hyperammonemia. We found that CH (patient 2)
was highly efficient in removing chloramphenicol
from the blood [11]. Despite high serum concentra-
tions entering the CH column, the concentrations
leaving the device were so low as to be unmeasur-
able. Thus, comparison of CII and HD was not pos-
sible [11]. Other work, however, has shown that
HD is relatively inefficient in clearing chloramphen-
icol [12]. In our view, the indications for CH in pe-
diatric patients are similar to those in adults and
should be considered in children with poisonings or
drug overdosages who meet the criteria suggested
by Winchester et al [3].
We conclude that CH can be performed without
the development of serious complications when me-
ticulous attention is given to technical details. Prob-
lems that must be overcome in the application of
presently available CII equipment to the infant or
small child include difficulty in blood access and the
large size of this equipment relative to that of the
child. A 100-g Hemacol charcoal column is pres-
ently available for clinical use only in England. A
150-g charcoal cartridge developed by the Gambro
Company is presently being evaluated in Europe
and in the USA but is not commercially available at
this time. It is hoped that this report will stimulate
the development of CH columns in sizes tailored
more appropriately to pediatric patients. We be-
lieve this would further diminish the risks associat-
ed with the application of this important therapeutic
modality to the pediatric patient.
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